Médica Sur, S.A. (MEDICAB) Fair Value & Analysis
Healthcare · MX · Market cap 5.4B MXN
Fair value as of: Jun 25, 2026
Analysis
Médica Sur, S.A. (MEDICAB) currently trades at 59.00 MXN, while our model-based Fair Value estimate is 130.14 MXN — implying the stock looks roughly 120.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Médica Sur, S.A.B. de C.V. operates as a healthcare hospital in Mexico. The company offers angiology, vascular, and endovascular surgery; bariatric surgery; cancer; cardiology; checkup and preventive medicine; children; dental; emergency; endocrinology; gastroenterology, hepatology, and endoscopy; general surgery; geriatric; and gynecology and obstetrics services. It also provides specialized surgery; neonatology; neurology, neurosurgery, and gamma knife radiosurgery; neurophysiology; nuclear medicine; orthopedic and traumatology; outpatient surgery; plastic surgery; robotic surgery; spine microsurgery; transplant; urology; vascular disease; and imagine and MRI unit services. In addition, the company offers accommodation; concierge; digital hospital and telemedicine; gourmet; assistance in paperwork and filing procedures with insurer; and tour and transportation services. Further, it provides medical services and diagnosis. The company was incorporated in 1966 and is based in Mexico…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Médica Sur, S.A. (MEDICAB) undervalued?
What is the fair value of MEDICAB?
What is the quality score of MEDICAB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.